Literature DB >> 15350358

The diagnostic accuracy of 18F-fluorodeoxyglucose PET/CT in patients with gynecological malignancies.

Dan Grisaru1, Benny Almog, Charles Levine, Ur Metser, Ami Fishman, Hedva Lerman, Joseph B Lessing, Einat Even-Sapir.   

Abstract

OBJECTIVE: To evaluate the diagnostic accuracy of integrated positron emission tomography/computerized tomography (PET/CT) in patients with gynecological cancer.
METHODS: Fifty-three consecutive patients with gynecologic malignancies were included. The patients were referred to our tertiary center to undergo a PET/CT scan. The sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of PET/CT were compared with the conventional imaging assessments [CT, magnetic resonance imaging (MRI) and ultrasonography (US)].
RESULTS: All tested values were higher for PET/CT than those for the conventional modalities: sensitivity 0.97 vs. 0.40, specificity 0.94 vs. 0.65, PPV 0.97 vs. 0.70, and NPV 0.94 vs. 0.34, respectively.
CONCLUSION: PET/CT is a reliable modality for assessing the extent of disease in patients with gynecologic malignancy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15350358     DOI: 10.1016/j.ygyno.2004.05.053

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  9 in total

1.  MR-PET fusion imaging in evaluating adnexal lesions: a preliminary study.

Authors:  V Fiaschetti; F Calabria; S Crusco; A Meschini; F Nucera; O Schillaci; G Simonetti
Journal:  Radiol Med       Date:  2011-09-02       Impact factor: 3.469

2.  Post-therapy surveillance of patients with uterine cancers: value of integrated FDG PET/CT in the detection of recurrence.

Authors:  Sandro Sironi; Maria Picchio; Claudio Landoni; Stefania Galimberti; Mauro Signorelli; Valentino Bettinardi; Patrizia Perego; Costantino Mangioni; Cristina Messa; Ferruccio Fazio
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-11-16       Impact factor: 9.236

Review 3.  Role and cost effectiveness of PET/CT in management of patients with cancer.

Authors:  Muhammad Wasif Saif; Ifigenia Tzannou; Nektaria Makrilia; Kostas Syrigos
Journal:  Yale J Biol Med       Date:  2010-06

4.  Efficacy of 18F-FDG PET/CT in the evaluation of patients with recurrent cervical carcinoma.

Authors:  Erik Mittra; Tarek El-Maghraby; Cesar A Rodriguez; Andrew Quon; I Ross McDougall; Sanjiv S Gambhir; Andrei Iagaru
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-12       Impact factor: 9.236

5.  Hybrid imaging is the future of molecular imaging.

Authors:  Rj Hicks; Ewf Lau; Ds Binns
Journal:  Biomed Imaging Interv J       Date:  2007-07-01

6.  Comparison of imaging-based gross tumor volume and pathological volume determined by whole-mount serial sections in primary cervical cancer.

Authors:  Ying Zhang; Jing Hu; Jianping Li; Ning Wang; Weiwei Li; Yongchun Zhou; Junyue Liu; Lichun Wei; Mei Shi; Shengjun Wang; Jing Wang; Xia Li; Wanling Ma
Journal:  Onco Targets Ther       Date:  2013-07-19       Impact factor: 4.147

Review 7.  Positron emission tomography alone, positron emission tomography-computed tomography and computed tomography in diagnosing recurrent cervical carcinoma: a systematic review and meta-analysis.

Authors:  Yi Xiao; Jia Wei; Yicheng Zhang; Weining Xiong
Journal:  Arch Med Sci       Date:  2014-05-13       Impact factor: 3.318

Review 8.  PET/CT and cross sectional imaging of gynecologic malignancy.

Authors:  Revathy B Iyer; Aparna Balachandran; Catherine E Devine
Journal:  Cancer Imaging       Date:  2007-10-01       Impact factor: 3.909

9.  Determination of an optimal standardized uptake value of fluorodeoxyglucose for positron emission tomography imaging to assess pathological volumes of cervical cancer: a prospective study.

Authors:  Ying Zhang; Jing Hu; Hong-Jun Lu; Jian-Ping Li; Ning Wang; Wei-Wei Li; Yong-Chun Zhou; Jun-Yue Liu; Sheng-Jun Wang; Jing Wang; Xia Li; Wan-Ling Ma; Li-Chun Wei; Mei Shi
Journal:  PLoS One       Date:  2013-11-12       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.